The potential impact of RV144-like vaccines in rural South Africa: A study using the STDSIM microsimulation model

Vaccine

Volumn 29, Issue 36, 2011, Pages 6100-6106

  Hontelez, Jan A C ^a,b,c   Nagelkerke, Nico ^a,d,e   Bärnighausen, Till ^c,f   Bakker, Roel ^a   Tanser, Frank ^c   Newell, Marie Louise ^c   Lurie, Mark N ^g   Baltussen, Rob ^a   de Vlas, Sake J ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

^d UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^e UNIVERSITY OF MANITOBA   (Canada)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g BROWN UNIVERSITY   (United States)

Author keywords

Cost effectiveness; HIV vaccine; Mathematical model; Microsimulation model; South Africa

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RV144; RV144 LIKE VACCINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVACCINATION; RURAL AREA; SEXUAL BEHAVIOR; SIMULATION; SOUTH AFRICA; VACCINATION;

EID: 80051471460     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.06.059     Document Type: Article

References (41)

1. Quinn T.C., Serwadda D. The future of HIV/AIDS in Africa: a shared responsibility. Lancet 2010, Epub ahead of print: 30 november 2010.
2. UNAIDS. Report on the Global AIDS epidemic 2010. Geneva: UNAIDS.
3. Padian N.S., McCoy S.I., Balkus J.E., Wasserheit JN Weighing the gold in the gold standard: challenges in HIV prevention research. AIDS 2010 2010, 24:621-635.
4. Burns D.N., Dieffenbach C.W., Vermund SH Rethinking prevention of HIV type 1 infection. Clin Infect Dis 2010, 51:725-731.
5. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2010, 361:2209-2220.
6. Kaldor J.M., Wilson D.P. How low can you go: the impact of a modestly effective HIV vaccine compared with male circumcision. AIDS 2010, 24:2573-2578.
7. Baggaley R.F., Ferguson N.M., Garnett G.P. The epidemiological impact of antiretroviral use predicted by mathematical models: a review. Emerg Themes Epidemiol 2005, 2:9.
8. Granich R.M., Gilks C.F., Dye C., De Cock K.M., Williams B.G. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009, 373:48-57.
9. Vissers D.C., Voeten H.A., Nagelkerke N.J., Habbema J.D., de Vlas SJ The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: a simulation study. PLoS One 2008, 3:e2077.
10. Baggaley R.F., Griffin J.T., Chapman R., Hollingsworth T.D., Nagot N., Delany S., et al. Estimating the public health impact of the effect of herpes simplex virus suppressive therapy on plasma HIV-1 viral load. AIDS 2009, 23:1005-1013.
11. Korenromp E.L., Bakker R., Gray R., Wawer M.J., Serwadda D., Habbema J.D. The effect of HIV, behavioural change, and STD syndromic management on STD epidemiology in sub-Saharan Africa: simulations of Uganda. Sex Transm Infect 2002, 78(Suppl. 1):i55-63.
12. Korenromp E.L., Van Vliet C., Grosskurth H., Gavyole A., Van der Ploeg C.P., Fransen L., et al. Model-based evaluation of single-round mass treatment of sexually transmitted diseases for HIV control in a rural African population. AIDS 2000, 14:573-593.
13. Korenromp E.L., Van Vliet C., Bakker R., De Vlas S.J., Habbema JD HIV spread and partnership reduction for different patterns of sexual behavior-a study with the microsimulation model STDSIM. Math Pop Studies 2000, 8:135-173.
14. Houlihan C.F., Bland R., Mutevedzi P., Lessells R.J., Ndirangu J., Thulare H., et al. Cohort Profile: Hlabisa HIV treatment and care programme. Int J Epidemiol 2011, 40:318-326.
15. Tanser F., Hosegood V., Barnighausen T., Herbst K., Nyirenda M., et al. Cohort profile: africa centre demographic information system (ACDIS) and population-based HIV survey. Int J Epidemiol 2008, 37:956-962.
16. Orroth K.K., Freeman E.E., Bakker R., Buve A., Glynn J.R., Boily M.C., et al. Understanding the differences between contrasting HIV epidemics in east and west Africa: results from a simulation model of the Four Cities Study. Sex Transm Infect 2007, 83(Suppl. 1):i5-16.
17. van der Ploeg C.P.B., Van Vliet C., De Vlas S.J., Ndinya-Achola J.O., Fransen L., van Oortmarssen G.J., et al. STDSIM: a microsimulation model for decision support in STD control. Interfaces 1998, 28:84-100.
18. Freeman E.E., White R.G., Bakker R., Orroth K.K., Weiss H.A., Buve A., et al. Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa. Vaccine 2009, 27:940-946.
19. Vissers D.C., DEV S.J., Bakker R., Urassa M., Voeten H.A. The impact of mobility on HIV control: a modelling study. Epidemiol Infect 2011, Published ahead of print: Feb 7.
20. Cooke G.S., Tanser F.C., Barnighausen T.W., Newell M.L. Population uptake of antiretroviral treatment through primary care in rural South Africa. BMC Public Health 2010, 10:585.
21. Attia S., Egger M., Muller M., Zwahlen M., Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009, 23:1397-1404.
22. Donnell D., Baeten J.M., Kiarie J., Thomas K.K., Stevens W., Cohen C.R., et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010, 375:2092-2098.
23. Walensky R.P., Wolf L.L., Wood R., Fofana M.O., Freedberg K.A., Martinson N.A., et al. When to start antiretroviral therapy in resource-limited settings. Ann Intern Med 2009, 151:157-166.
24. WHO. Rapid Advice: Antiretroviral Therapy For HIV Infected In Adults And Adolescents. 2009 Geneva: World Health Organization.
25. Demographic and Health Survey of South Africa. Pretoria: Department of Health; 2003.(accessed April 30, 2010, at ). http://www.measuredhs.com/countries/country_main.cfm%3F%20ctry_id=55%26c=South%20Africa.
26. Colvin M., Abdool Karim S.S., Connolly C., Hoosen A.A., Ntuli N. HIV infection and asymptomatic sexually transmitted infections in a rural South African community. Int J STD AIDS 1998, 9:548-550.
27. Demographic and Health Survey of South Africa. Pretoria: Department of health; 1998. (accessed April 30, 2010, at ). http://www.doh.gov.za/facts/1998/sadhs98/.
28. Newman P.A., Roungprakhon S., Tepjan S., Yim S. Preventive HIV vaccine acceptability and behavioral risk compensation among high-risk men who have sex with men and transgenders in Thailand. Vaccine 2009, 28:958-964.
29. Kelly H., Attia J., Andrews R., Heller R.F. The number needed to vaccinate (NNV) and population extensions of the NNV: comparison of influenza and pneumococcal vaccine programmes for people aged 65 years and over. Vaccine 2004, 22:2192-2198.
30. Harling G., Wood R. The evolving cost of HIV in South Africa: changes in health care cost with duration on antiretroviral therapy for public sector patients. J Acquir Immune Defic Syndr 2007, 45:348-354.
31. Evans D.B., Lim S.S., Adam T., Edejer T.T. Evaluation of current strategies and future priorities for improving health in developing countries. BMJ 2005, 331:1457-1461.
32. WHO. Burden of Disease estimates. (Available from ). http://www.who.int/healthinfo/global_burden_disease/estimates_regional/en/index.html.
33. UNDP (2010) International Human Development Indicators. United Nations Development Programme.
34. WHO (2003) Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis. Geneva: World Health Organization.
35. Garnett G.P. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis 2005, 191(Suppl. 1):S97-106.
36. Tebit D.M., Arts E.J. Tracking a century of global expansion and evolution of HIV to drive understanding and to combat disease. Lancet Infect Dis 2011, 11:45-56.
37. Jehu-Appiah C., Baltussen R., Acquah C., Aikins M., d'Almeida S.A., Bosu W.K., et al. Balancing equity and efficiency in health priorities in Ghana: the use of multicriteria decision analysis. Value Health 2008, 11:1081-1087.
38. Binagwaho A., Pegurri E., Muita J., Bertozzi S. Male circumcision at different ages in Rwanda: a cost-effectiveness study. PLoS Med 2010, 7:e1000211.
39. Uthman O.A., Popoola T.A., Uthman M.M., Aremu O. Economic evaluations of adult male circumcision for prevention of heterosexual acquisition of HIV in men in sub-Saharan Africa: a systematic review. PLoS One 2010, 5:e9628.
40. Bärnighausen T., Bloom D.E., Canning D., Friedman A., Levine O., O'Brien J., et al. Rethinking the benefits and costs of childhood vaccination: The example of the Haemophilus influenzae type B vaccine. Vaccine 2011, 29:2371-2380.
41. Dolin R. HIV vaccine trial results-an opening for further research. N Engl J Med 2009, 361:2279-2280.